



The Southern California Drug Metabolism Discussion Group
presents:

Challenges & Opportunities in Drug Development from a Drug Safety and Metabolism Perspective

Dr. Jack H. Dean

Professor
Dept of Pharmacology/Toxicology
University of Arizona
Tucson, AZ

Dr. Thomas Baillie

Dean
School of Pharmacy
University of Washington
Seattle, WA

Presentation Synopsis:

The first seminar will review three areas concerning the Biopharmaceutical Industry: 1) factors forcing transformation of the industry; 2) difficulties and strategies for filling the product gap; and, 3) use of toxicogenomics as a selection tool for NCEs. Transformation of large pharma is being driven by increasing R&D costs with declining productivity, wholesale patent expiration of blockbuster drugs, and increasing regulatory demands. These factors will create a dramatic transformation of large and small pharma which will be discussed. Filling the gap with NCEs is the biggest challenge for our industry and will require a renewed effort to find rapid methods to explore both the chemical and biological space to define new targets and select lead NCEs. The use of nano-scale solid phase combinatorial chemistry techniques as a tool to fill the gap will be discussed. The challenge is to rapidly explore the safety of these candidates using in vitro toxicological tools such as toxicogenomics.

The metabolic transformation of a chemically stable molecule to a reactive, electrophilic intermediate generally is considered to be an undesirable feature of a drug candidate, and the phenomenon of "metabolic activation" has attracted widespread attention in drug discovery and development programs. The second half of the seminar series will focus on one aspect of metabolic activation, namely time-dependent inhibition of cytochrome P450 enzymes. Mechanistic studies on time-dependent inhibition can prove valuable in redirecting lead optimization efforts towards analogs that lack such a liability, and this approach will be exemplified in the case of the selective estrogen receptor modulator, raloxifene (Evista).

Tuesday, May 19, 2009

4:30 p.m. Registration and Buffet Dinner
6:30 p.m. Presentation Begins

Salk Institute for Biological Studies
Frederic de Hoffmann Auditorium
10010 North Torrey Pines Road

Price \$20 Advance Registration, \$20 At the Door (includes buffet dinner and soft drinks / beer / wine)

The SCDMDG was established in 2003 as a forum for Southern California scientists working in drug metabolism in both academic and industrial settings to meet and discuss issues and share information for the public good.



Space is Limited—Register Early to Guarantee Your Attendance!

To Register for SCDMDG - Dean/Baillie, May 19, 2009 send payment with this form to:

5310 Eastgate Mall, San Diego, CA 92121

\$20/person in Advance, \$20 at the Door. Please make CHECKS payable to SCDMDG

Name(s): _____
Company: _____
Address: _____
Phone: _____
Number Attending: _____ Amount Enclosed: \$ _____

For more information call: 858.458.9305 • e-mail: scdmdg@hbri.org • website: www.scdmdg.org